INGLEWOOD, Calif., Jan. 22,
2025 /PRNewswire/ -- ImaginAb, Inc., announces that
it has entered into an agreement to sell a pipeline of
next-generation therapeutic candidates, proprietary novel biologics
technology platform, and a protein engineering and discovery
research facility to Telix Pharmaceuticals Limited (ASX: TLX;
Nasdaq: TXL).
Following the closing of this transaction, ImaginAb Inc., will
focus on developing its lead imaging candidate, CD8 ImmunoPET,
which is currently in Phase 2 clinical trials and has been
licensed by numerous pharmaceutical and biotech companies for use
in imaging within immunotherapy clinical trials, primarily in
oncology. In addition, ImaginAb will continue to partner in
advancing the pivotal prostate cancer imaging agent, which is
currently being evaluated in Phase 2 clinical trials and as a
surgical resection tool.
Dr. Anna Wu, Founder of ImaginAb,
commented, "We are very pleased that Telix recognizes the potential
of our novel biological technology platform including enabling
Telix to explore new disease areas with state-of-the-art
radiotherapeutic technology. These radiopharmaceutical agents
represent the culmination of significant effort and resources by
our scientific team. I extend my congratulations to everyone
at ImaginAb for reaching this significant milestone. This
transaction further validates our novel minibody platform."
Dr. Wu continued, "With the sale of our radiopharmaceutical
platform, ImaginAb will continue the development of its CD8
platform. We are encouraged that numerous pharmaceutical and
biotech companies have incorporated our technology in their
immuno-oncology clinical trials."
Jefferies LLC and Stifel, Nicolaus & Company, Incorporated
served as financial advisors to ImaginAb on the transaction.
About ImaginAb, Inc.
ImaginAb, Inc. is a clinical stage, revenue-generating global
biotechnology company developing the next generation of
radiopharmaceutical and imaging agent products. These patented
products contain engineered antibodies that maintain the
specificity of full-length antibodies while remaining biologically
inert in the body. Used with widely available positron emission
tomography (PET) and optical imaging technology, these novel
targeting agents are able to bind specifically to cell surface
targets.
The company is backed by top tier venture capital firms and
strategic corporate firms including, Adage Capital, The Cycad
Group, Norgine Ventures, Innoviva, Jim
Pallotta of the Raptor Group, The Parker Institute for
Cancer Immunotherapy, and Merck (MSD) Pharma. For more information
about ImaginAb's pipeline and technology,
visit www.imaginab.com.
About CD8 ImmunoPET
The 89Zr CD8 ImmunoPET technology (zirconium Zr 89
crefmirlimab berdoxam) is a [89Zr]-labelled minibody that
binds the CD8 receptor on human T cells and is used for
quantitative, non-invasive PET imaging of CD8+ cells in patients.
CD8+ cells are the main effector cells involved in the immune
response against tumor cells induced by immunotherapies and they
also play a key role in multiple autoimmune diseases. As such,
quantitative imaging of CD8+ cells can be used to diagnose the
immune status of a patient, to measure the efficacy of
immunotherapies and predict patient outcomes.
About Optical PSMA
The Optical PSMA Imaging Agent (IR-800 IAB2
Minibody) is a fluorescent labelled minibody that binds the
PSMA receptor present on cancer cells including prostate
cancer and is used for quantitative, non-invasive PET imaging of
PSMA+ cells in patients undergoing surgery to remove cancerous
tissue . As such, imaging of PSMA + cells may be used to
guide clinicians during surgery to identify cancerous tissue and
aid tissue resection.
Logo -
https://mma.prnewswire.com/media/2603972/ImaginAb_Main_Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/imaginab-inc-innovative-biologics-technology-platform-acquired-by-telix-to-enable-next-generation-therapeutic-assets-discovery-302357703.html
